Published in Oncogene on July 18, 2011
HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene (2012) 4.30
The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ (2013) 2.41
Analysis of microRNA-target interactions across diverse cancer types. Nat Struct Mol Biol (2013) 1.41
miR-18a impairs DNA damage response through downregulation of ataxia telangiectasia mutated (ATM) kinase. PLoS One (2011) 1.20
Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. Nat Commun (2013) 1.19
TGFβR2 is a major target of miR-93 in nasopharyngeal carcinoma aggressiveness. Mol Cancer (2014) 1.15
MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis. Carcinogenesis (2013) 1.10
Imperfect centered miRNA binding sites are common and can mediate repression of target mRNAs. Genome Biol (2014) 1.08
Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis (2013) 1.08
Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer (2014) 1.07
miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. Oncogene (2013) 1.06
MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med (2013) 1.05
Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs. BMC Cancer (2012) 1.04
Mechanism of action of phenethylisothiocyanate and other reactive oxygen species-inducing anticancer agents. Mol Cell Biol (2014) 1.04
CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood (2013) 1.02
MicroRNAs and lung cancers: from pathogenesis to clinical implications. Front Med (2012) 1.00
miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget (2015) 0.97
Celastrol decreases specificity proteins (Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells. Carcinogenesis (2012) 0.97
Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. Genome Biol (2013) 0.97
MicroRNAs in cancer therapeutic response: Friend and foe. World J Clin Oncol (2014) 0.96
Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters. Mol Cancer Ther (2012) 0.96
DNA methylation, its mediators and genome integrity. Int J Biol Sci (2015) 0.96
Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype. World J Gastroenterol (2013) 0.96
MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers. Breast Cancer Res (2014) 0.92
Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs. Anticancer Agents Med Chem (2012) 0.92
Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Mol Cancer Ther (2012) 0.90
microRNA-93 promotes cell proliferation via targeting of PTEN in Osteosarcoma cells. J Exp Clin Cancer Res (2015) 0.90
Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers. PLoS One (2012) 0.88
REACTIVE OXYGEN SPECIES AND COLORECTAL CANCER. Curr Colorectal Cancer Rep (2013) 0.87
An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer. Genome Biol (2015) 0.87
miR-106a-5p inhibits the proliferation and migration of astrocytoma cells and promotes apoptosis by targeting FASTK. PLoS One (2013) 0.86
Peroxisome proliferator activated receptor-α/hypoxia inducible factor-1α interplay sustains carbonic anhydrase IX and apoliprotein E expression in breast cancer stem cells. PLoS One (2013) 0.86
A Comprehensive Review of Dysregulated miRNAs Involved in Cervical Cancer. Curr Genomics (2014) 0.86
Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters. PLoS One (2012) 0.83
Zinc finger and BTB domain-containing protein 3 is essential for the growth of cancer cells. BMB Rep (2014) 0.83
The cannabinoid WIN 55,212-2 decreases specificity protein transcription factors and the oncogenic cap protein eIF4E in colon cancer cells. Mol Cancer Ther (2013) 0.82
Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. Genome Med (2015) 0.82
MicroRNA-Specificity Protein (Sp) Transcription Factor Interactions and Significance in Carcinogenesis. Curr Pharmacol Rep (2015) 0.81
The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer. BMC Cancer (2015) 0.80
An epigenetic auto-feedback loop regulates TGF-β type II receptor expression and function in NSCLC. Oncotarget (2015) 0.79
The transcriptional repressor ZBTB4 regulates EZH2 through a MicroRNA-ZBTB4-specificity protein signaling axis. Neoplasia (2014) 0.78
Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer. Cell Death Dis (2017) 0.77
EMMPRIN, SP1 and microRNA-27a mediate physcion 8-O-β-glucopyranoside-induced apoptosis in osteosarcoma cells. Am J Cancer Res (2016) 0.76
Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers. BMC Cancer (2015) 0.76
A MicroRNA/Ubiquitin Ligase Feedback Loop Regulates Slug-Mediated Invasion in Breast Cancer. Neoplasia (2017) 0.75
MicroRNA-17/20a impedes migration and invasion via TGF-β/ITGB6 pathway in esophageal squamous cell carcinoma. Am J Cancer Res (2016) 0.75
Post-transcriptional regulation of MTA family by microRNAs in the context of cancer. Cancer Metastasis Rev (2014) 0.75
Differential Sensitivity of Target Genes to Translational Repression by miR-17~92. PLoS Genet (2017) 0.75
Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting. Oncotarget (2016) 0.75
Benzylisothiocyanate (BITC) Induces ROS-dependent Repression of STAT3 by Downregulation of Specificity Proteins in Pancreatic Cancer. J Biol Chem (2016) 0.75
Prognostic role of miR-17-92 family in human cancers: evaluation of multiple prognostic outcomes. Oncotarget (2017) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Prediction of mammalian microRNA targets. Cell (2003) 53.70
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell (2005) 5.04
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther (2007) 3.84
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature (2005) 3.75
Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One (2008) 3.68
The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res (2007) 3.40
Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell (2005) 3.39
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther (2007) 2.53
Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol (2006) 2.37
MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood (2008) 2.29
mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther (2010) 2.00
Born to bind: the BTB protein-protein interaction domain. Bioessays (2006) 1.99
microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A (2010) 1.97
A family of human zinc finger proteins that bind methylated DNA and repress transcription. Mol Cell Biol (2006) 1.94
Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res (2004) 1.87
Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet (2003) 1.77
Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res (2008) 1.76
Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res (2009) 1.74
Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res (2007) 1.64
Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol Pharmacol (2010) 1.44
Sequence-specific recognition of methylated DNA by human zinc-finger proteins. Nucleic Acids Res (2010) 1.41
Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem (2002) 1.37
Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth. Cancer Res (2010) 1.37
Proto-oncogene FBI-1 (Pokemon/ZBTB7A) represses transcription of the tumor suppressor Rb gene via binding competition with Sp1 and recruitment of co-repressors. J Biol Chem (2008) 1.36
Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res (2010) 1.33
Functional analysis of the role of POK transcriptional repressors. Brief Funct Genomic Proteomic (2007) 1.33
Cloning and characterization of the 5'-flanking region of the human transcription factor Sp1 gene. J Biol Chem (2001) 1.29
miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat (2010) 1.26
Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation. EMBO J (2008) 1.23
The role of Sp1 family members, the proximal GC-rich motifs, and the upstream enhancer region in the regulation of the human cell cycle inhibitor p21WAF-1/Cip1 gene promoter. Biochemistry (2002) 1.16
FBI-1 can stimulate HIV-1 Tat activity and is targeted to a novel subnuclear domain that includes the Tat-P-TEFb-containing nuclear speckles. Mol Biol Cell (2002) 1.14
RIN ZF, a novel zinc finger gene, encodes proteins that bind to the CACC element of the gastrin promoter. J Biol Chem (1999) 1.09
ZBTB2, a novel master regulator of the p53 pathway. J Biol Chem (2009) 1.06
The proto-oncogene BCL-6 in normal and malignant B cell development. Hematol Oncol (2002) 1.01
Testicular germ cell apoptosis in Bcl6-deficient mice. Development (2001) 0.98
A novel POK family transcription factor, ZBTB5, represses transcription of p21CIP1 gene. J Biol Chem (2009) 0.92
Transcriptional regulation of the 5'-flanking region of the human transcription factor Sp3 gene by NF-1, c-Myb, B-Myb, AP-1 and E2F. Biochim Biophys Acta (2008) 0.84
Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Environ Health Perspect (1998) 6.08
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet (1999) 5.29
HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene (2012) 4.30
Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol (1997) 3.60
Retention times and electron-capture detector responses of some individual chlorobiphenyls. Bull Environ Contam Toxicol (1972) 2.46
Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol (2001) 2.29
Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res (1999) 2.23
Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol. Mol Cell Endocrinol (1998) 2.18
Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev (2000) 2.15
Increased incidence of herpes zoster in the setting of cytomegalovirus preemptive therapy after kidney transplantation. Transpl Infect Dis (2013) 2.09
High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology (2000) 2.06
Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem (2000) 2.00
Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol (1997) 1.87
Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol (2008) 1.86
Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys (2000) 1.74
Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst (1998) 1.71
Mechanisms of ligand-induced aryl hydrocarbon receptor-mediated biochemical and toxic responses. Toxicol Pathol (1998) 1.70
Interface ferromagnetism and orbital reconstruction in BiFeO3-La(0.7)Sr(0.3)MnO3 heterostructures. Phys Rev Lett (2010) 1.68
Immunosuppressive and monooxygenase induction activities of polychlorinated diphenyl ether congeners in C57BL/6N mice: quantitative structure-activity relationships. Toxicol Appl Pharmacol (1990) 1.65
Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Neurology (2008) 1.63
Hydroxylated polychlorinated biphenyls (PCBs) as estrogens and antiestrogens: structure-activity relationships. Toxicol Appl Pharmacol (1997) 1.61
A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant (2011) 1.60
Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer (2004) 1.58
Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol Endocrinol (1999) 1.57
Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem (2001) 1.55
Enterococcus avium bacteremia: a 12-year clinical experience with 53 patients. Eur J Clin Microbiol Infect Dis (2011) 1.53
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol (2004) 1.53
Structure-dependent, competitive interaction of hydroxy-polychlorobiphenyls, -dibenzo-p-dioxins and -dibenzofurans with human transthyretin. Chem Biol Interact (1993) 1.52
No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer (1998) 1.52
Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem (1999) 1.50
Polychlorinated biphenyls: metabolic behavior of pure isomers in pigeons, rats, and brook trout. Science (1972) 1.48
Analysis of initial and follow-up CT findings in patients with invasive pulmonary aspergillosis after solid organ transplantation. Clin Radiol (2012) 1.44
The effect of environment on the free and hydrosoluble sterols of Mucor rouxii. Biochim Biophys Acta (1973) 1.44
Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), and dibenzofurans (PCDFs) as antiestrogens in MCF-7 human breast cancer cells: quantitative structure-activity relationships. Toxicol Appl Pharmacol (1993) 1.40
Polychlorinated biphenyls (PCBs) and polybrominated biphenyls (PBBs): biochemistry, toxicology, and mechanism of action. Crit Rev Toxicol (1984) 1.39
Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene (2012) 1.39
Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis. J Eur Acad Dermatol Venereol (2011) 1.39
Postprandial hypoglycaemia due to insulin lispro. Diabet Med (2004) 1.38
Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis (1998) 1.38
Sexuality and the management of BPH with alfuzosin (SAMBA) trial. Int J Impot Res (2008) 1.38
Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem Pharmacol (1996) 1.35
Process evaluation results from a school- and community-linked intervention: the Trial of Activity for Adolescent Girls (TAAG). Health Educ Res (2008) 1.34
Percutaneous vertebroplasty for vertebral compression fractures with and without intravertebral clefts. J Bone Joint Surg Br (2006) 1.33
Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol (2008) 1.33
PCBs: structure-function relationships and mechanism of action. Environ Health Perspect (1985) 1.32
Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. Anticancer Res (1998) 1.32
Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant (2003) 1.32
MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors. Oncogene (2006) 1.31
Differential interaction of the methoxychlor metabolite 2,2-bis-(p-hydroxyphenyl)-1,1,1-trichloroethane with estrogen receptors alpha and beta. Endocrinology (1999) 1.29
Binding of polychlorinated biphenyls classified as either phenobarbitone-, 3-methylcholanthrene- or mixed-type inducers to cytosolic Ah receptor. Chem Biol Interact (1982) 1.29
PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ (2010) 1.28
Interaction of methoxychlor and related compounds with estrogen receptor alpha and beta, and androgen receptor: structure-activity studies. Mol Pharmacol (2000) 1.28
Overexpression of nucleoside diphosphate kinase (Nm23) in solid tumours. Eur J Cancer (1991) 1.27
Immunosuppressive activity of polychlorinated biphenyl mixtures and congeners: nonadditive (antagonistic) interactions. Fundam Appl Toxicol (1995) 1.27
Polychlorinated biphenyls as inducers of hepatic microsomal enzymes: structure-activity rules. Chem Biol Interact (1980) 1.25
Antiestrogenic activity of hydroxylated polychlorinated biphenyl congeners identified in human serum. Toxicol Appl Pharmacol (1997) 1.24
Structure-dependent induction of CYP2B by polychlorinated biphenyl congeners in female Sprague-Dawley rats. Biochem Pharmacol (1995) 1.23
Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem (1994) 1.20
Integration of papillomavirus DNA near myc genes in genital carcinomas and its consequences for proto-oncogene expression. J Virol (1991) 1.20
The mechanism of chlorobiphenyl metabolism. J Agric Food Chem (1975) 1.20
hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol (2007) 1.20
The in vitro metabolism, macromolecular binding and bacterial mutagenicity of 4-chloribiphenyl, a model PCB substrate. Res Commun Chem Pathol Pharmacol (1976) 1.19
Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene (2010) 1.18
Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells. Mol Cell Biol (1995) 1.17
Human Contamination of the Marine Environment-Arthur Harbor and McMurdo Sound, Antarctica. Environ Sci Technol (1995) 1.17
Estrogenic activity of a dieldrin/toxaphene mixture in the mouse uterus, MCF-7 human breast cancer cells, and yeast-based estrogen receptor assays: no apparent synergism. Endocrinology (1997) 1.16
Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma. Virology (2012) 1.16
Interactions of nuclear receptor coactivator/corepressor proteins with the aryl hydrocarbon receptor complex. Arch Biochem Biophys (1999) 1.15
Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology (1998) 1.14
Transcriptional activation of transforming growth factor alpha by estradiol: requirement for both a GC-rich site and an estrogen response element half-site. J Mol Endocrinol (2000) 1.14
Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia (2005) 1.14
Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol (1998) 1.13
Transcriptional activation of c-fos protooncogene by 17beta-estradiol: mechanism of aryl hydrocarbon receptor-mediated inhibition. Mol Endocrinol (1999) 1.13
Acupuncture for obesity: a systematic review and meta-analysis. Int J Obes (Lond) (2009) 1.13
Identification of a motif within the 5' regulatory region of pS2 which is responsible for AP-1 binding and TCDD-mediated suppression. Biochemistry (1997) 1.12
Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol (1994) 1.12
Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant (2006) 1.11
The metabolism of 4-chlorobiphenyl in the pig. Can J Physiol Pharmacol (1975) 1.11
The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53. Oncogene (2011) 1.10
Risk factors for false-negative results of T-SPOT.TB and tuberculin skin test in extrapulmonary tuberculosis. Infection (2013) 1.10
Inhibition of 7,12-dimethylbenzanthracene-induced rat mammary tumor growth by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Lett (1994) 1.10
Role of estrogen receptor/Sp1 complexes in estrogen-induced heat shock protein 27 gene expression. Mol Endocrinol (1996) 1.09
Cost-effectiveness of monolayers and human papillomavirus testing compared to that of conventional Papanicolaou smears for cervical cancer screening: protocol of the study of the French Society of Clinical Cytology. Diagn Cytopathol (2001) 1.08
Identification of 3'-methoxy-4'-nitroflavone as a pure aryl hydrocarbon (Ah) receptor antagonist and evidence for more than one form of the nuclear Ah receptor in MCF-7 human breast cancer cells. Arch Biochem Biophys (1995) 1.08
The cytosolic receptor binding affinities and AHH induction potencies of 29 polynuclear aromatic hydrocarbons. Toxicol Lett (1986) 1.07
Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. J Steroid Biochem Mol Biol (1998) 1.06
Failure of chloro-S-triazine-derived compounds to induce estrogen receptor-mediated responses in vivo and in vitro. Fundam Appl Toxicol (1996) 1.06
Lysosomal membrane labilization by DDT, DDE and polychlorinated biphenyls (PCB). Res Commun Chem Pathol Pharmacol (1976) 1.06
Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer. Genes Chromosomes Cancer (1998) 1.06
RB1 and TP53 pathways in radiation-induced sarcomas. Oncogene (2007) 1.05
Decrease of initial CD4+ T-cell counts at the time of diagnosis of HIV infection in Korea; 1988-2006. Int J STD AIDS (2010) 1.05
Polybrominated dibenzo-p-dioxins and related compounds: quantitative in vivo and in vitro structure-activity relationships. Toxicology (1987) 1.05
Prevention of premature senescence requires JNK regulation of Bcl-2 and reactive oxygen species. Oncogene (2009) 1.04
Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases. Br J Surg (2003) 1.04
Differential gene expression of activating Fcγ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clin Microbiol Infect (2013) 1.04
Polychlorinated biphenyls as phenobarbitone-type inducers of microsomal enzymes. Structure-activity relationships for a series of 2,4-dichloro-substituted congeners. Biochem Pharmacol (1983) 1.04
Potency of combined estrogenic pesticides. Science (1997) 1.04
Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists. Biochem Pharmacol (1996) 1.04
Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins. J Biol Chem (2000) 1.04